Rachel Beller’s practice focuses on royalty monetization transactions involving the acquisition and financing of pharmaceutical royalty streams. Rachel also assists clients with bank finance transactions, including the negotiation of, and the ongoing compliance under, secured and unsecured domestic and cross-border syndicated term and revolving credit facilities. She has experience in acquisition finance, structured finance and other asset-based transactions.
New York University School of Law, J.D., magna cum laude, Order of the Coif, 2011
Brandeis University, B.A., summa cum laude, Phi Beta Kappa, 2008
Bar and Court Admissions
BAR ADMISSIONS
New York
Experience
ROYALTY MONETIZATION MATTERS
Purdue Research Foundation (an affiliate of Purdue University) in the monetization of a portion of its royalty interests in Pluvicto for over $100 million
Two European non-profits in their monetization of a portion of their royalty interests in a pharmaceutical product for the treatment of certain seizures
A group of individual inventors affiliated with a US-based university in the monetization of their royalty interests in a pharmaceutical product for the treatment of certain cancers
Eisai Co., Ltd., a global pharmaceutical company headquartered in Japan, in its 2019 monetization of its royalty interests in Tazemetostat for up to $330 million, consisting of an up-front payment of $110 million for a certain portion of the royalty interests and up to $220 million in additional payments for the remainder of the royalty interests upon FDA approval of Tazemetostat for certain indications
LifeArc (formerly MRC Technology), a leading UK-based medical research charity, in its 2016 sale of a small proportion of its royalty rights in Keytruda for $150 million (approximately £115 million)
University of Newcastle upon Tyne, a UK public research university, in its monetization of a portion of its royalty interests in Rubraca
Cold Spring Harbor Laboratory, a leading not-for-profit research institute founded in 1890 and home to eight Nobel Prize winners, in its structured monetization of a portion of its royalty interests in the first product approved by the FDA for the treatment of a rare genetic disorder
Boston Children’s Hospital, one of the leading pediatric medical centers in the United States, in its monetization of a portion of its royalty interests in Vonvendi
The Walter and Eliza Hall Institute of Medical Research, Australia’s oldest medical research institute, in its monetization of a portion of its royalty interests in Venetoclax for up to U.S.$325 million (A$406 million), consisting of an up-front payment of U.S.$250 million and up to U.S.$75 million of additional payments upon the attainment of certain milestones, the largest royalty monetization by a non-profit institution outside the United States and the United Kingdom
Dana-Farber Cancer Institute, a world leader in cancer research, in two royalty monetizations, including its sale of a portion of its royalty interests in various Programmed Death Ligand-1 (PD-L1) cancer drugs for an up-front payment of $100 million and up to $68 million of additional payments upon the satisfaction of certain conditions
Group of Inventors associated with UCLA in connection with the sale by UCLA of royalty rights in respect of Xtandi for an up-front cash payment of $1.14 billion and potential additional payments based on future Xtandi sales, the largest royalty monetization done by an inventor group
Northwestern University in the sale of a portion of its worldwide royalty interests in Lyrica
BANK FINANCE MATTERS
Aristocrat Leisure Limited in its senior secured term loan and revolving credit facility
Goodyear Tire & Rubber Company in its global debt financings, including first and second lien credit facilities, multiple issuances of high yield bonds, and credit facilities in Europe and Latin America
LIN Media in its senior secured credit facilities
* - Ms. Beller handled the above representations prior to joining Foley Hoag.
Honors & Involvement
HONORS
NYU Journal of Law & Business, Executive Editor for Student Notes
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
